News | August 04, 2022
Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar
Biopharma and CROs to benefit from simplified access to global research sites
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Better serving global partners and advancing healthcare innovation
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
ABDM Hackathon Round 1 – Kickstarting Unified Health Interface (UHI) is being held from 14th to 17th July 2022 as a hybrid event
Upgrades and global expansion provide additional control, visibility, reliability and recovery for patient-critical, time-and temperature-sensitive products
To strengthen the integrated human-centric preventive health screening ‘Phygital’ ecosystem in India
Subscribe To Our Newsletter & Stay Updated
